+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2020

  • ID: 5117119
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 61 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AiCuris GmbH & Co KG
  • Astellas Pharma Inc
  • Dobecure SL
  • NanoViricides Inc
  • Provention Bio Inc
  • Squarex LLC
  • MORE
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis – Pipeline Review, H1 2020, provides an overview of the Herpes Labialis (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Herpes Labialis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 1 respectively.

Herpes Labialis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Labialis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Labialis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AiCuris GmbH & Co KG
  • Astellas Pharma Inc
  • Dobecure SL
  • NanoViricides Inc
  • Provention Bio Inc
  • Squarex LLC
  • MORE
  • Introduction
  • Report Coverage
  • Herpes Labialis (Oral Herpes) - Overview
  • Herpes Labialis (Oral Herpes) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Herpes Labialis (Oral Herpes) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development
  • AiCuris GmbH & Co KG
  • Astellas Pharma Inc
  • Brandenburg Antiinfektiva GmbH
  • Dobecure SL
  • NanoViricides Inc
  • Provention Bio Inc
  • Shulov Innovative Science Ltd
  • Squarex LLC
  • Vironova Medical AB
  • Herpes Labialis (Oral Herpes) - Drug Profiles
  • amenamevir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aspidasept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • B-220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ethamsylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NVHHV-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pritelivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRV-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Herpes Labialis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • squaric acid dibutyl ester - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZEP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZEP-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Herpes Labialis (Oral Herpes) - Dormant Projects
  • Herpes Labialis (Oral Herpes) - Discontinued Products
  • Herpes Labialis (Oral Herpes) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 05, 2019: Squarex announces positive results from completed phase 2 study of SQX770 in the prevention of recurrent herpes labialis
  • Jul 01, 2019: Squarex appoints biopharmaceutical industry veteran Jack V. Talley as chief executive officer
  • Feb 14, 2019: Squarex Announces Publication of Clinical Results for SQX770 for the Prevention of Herpes Outbreaks in Immunity, Inflammation and Disease
  • Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
  • May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study
  • Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
  • Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Information
  • Disclaimer
List of Tables
  • Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Astellas Pharma Inc, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Brandenburg Antiinfektiva GmbH, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Dobecure SL, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Provention Bio Inc, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Squarex LLC, H1 2020
  • Herpes Labialis (Oral Herpes) - Pipeline by Vironova Medical AB, H1 2020
  • Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2020
  • Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • AiCuris GmbH & Co KG
  • Astellas Pharma Inc
  • Brandenburg Antiinfektiva GmbH
  • Dobecure SL
  • NanoViricides Inc
  • Provention Bio Inc
  • Shulov Innovative Science Ltd
  • Squarex LLC
  • Vironova Medical AB
Note: Product cover images may vary from those shown
Adroll
adroll